Therapeutic agents and methods
The invention provides glucocorticoid receptor antagonists for treatment of infection, neoplasia, and fatty liver disease.
1. A compound selected from the group consisting of:
TPR-1, or pharmaceutically acceptable salts thereof;
OR-1, or pharmaceutically acceptable salts thereof;
KM-1, or pharmaceutically acceptable salts thereof;
TCY-1, or pharmaceutically acceptable salts thereof;
PT157, or pharmaceutically acceptable salts thereof;
PT158, or pharmaceutically acceptable salts thereof;
PT159, or pharmaceutically acceptable salts thereof;
PT160, or pharmaceutically acceptable salts thereof;
PT162, or pharmaceutically acceptable salts thereof;
PT163, or pharmaceutically acceptable salts thereof;
PT164, or pharmaceutically acceptable salts thereof;
PT165, or pharmaceutically acceptable salts thereof;
PT166, or pharmaceutically acceptable salts thereof;
PT167, or pharmaceutically acceptable salts thereof,
and combinations thereof.
2. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 and at least one pharmaceutically acceptable excipient.
3. The pharmaceutical composition of claim 2 in a dosage form selected from the group consisting of a minicapsule, a capsule, a tablet, an implant, a troche, a lozenge, a minitablet, a temporary or permanent suspension, an injectable, an ovule, a suppository, a wafer, a chewable tablet, a quick or fast dissolving tablet, an effervescent tablet, a buccal or sublingual solid, a granule, a film, a sprinkle, a pellet, a topical formulation, a patch, a bead, a pill, a powder, a triturate, a smart pill, a smart capsule, a platelet, a strip, and a sachet.
4. The pharmaceutical composition of claim 2 in a dosage form for topical application, and at least one pharmaceutically acceptable excipient.
5. The pharmaceutical composition of claim 2 in a dosage form for topical application wherein said formulation is in a form selected from the group consisting of: cream, lotion, gel, oil, ointment, suppository, spray, foam, liniment, aerosol, buccal and sublingual tablet or a transdermal device or patch for absorption through the skin or mucous membranes.
6. A kit for treating or preventing a condition in a patient, the kit comprising: (a) the pharmaceutical composition of claim 2 in a therapeutically effective amount; and (b) at least one blister package; a lidded blister; a blister card or packet; a clamshell; an intravenous (IV) package, IV packette or IV container; a tray or a shrink wrap comprising the pharmaceutical composition of (a) and instructions for using the pharmaceutical composition.